The summary below is from the full report titled “Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes.” It is in the 19 July 2005 issue of Annals of Internal Medicine (volume 143, pages 89-99). The authors are A.B. Rosen, M.B. Hamel, M.C. Weinstein, D.M. Cutler, A.M. Fendrick, and S. Vijan.
The Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Patients with Diabetes. Ann Intern Med. 2005;143:I–21. doi: https://doi.org/10.7326/0003-4819-143-2-200507190-00002
Download citation file:
Published: Ann Intern Med. 2005;143(2):I-21.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism, Healthcare Delivery and Policy.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use